791807-66-4

Usage

Uses

Used in Organic Synthesis:
(R)-azetidin-2-ylmethanol hydrochloride is used as a reagent in organic synthesis for its ability to facilitate the creation of chiral compounds. Its unique structure allows for the development of complex molecules with specific stereochemistry, which is crucial in the synthesis of pharmaceuticals and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (R)-azetidin-2-ylmethanol hydrochloride is used as a building block for the synthesis of biologically active molecules. Its chiral nature makes it a valuable component in the development of drugs that target specific receptors or enzymes, potentially leading to more effective and selective medications.
Used in Medicinal Chemistry:
(R)-azetidin-2-ylmethanol hydrochloride is employed in medicinal chemistry as a key intermediate in the design and synthesis of novel therapeutic agents. Its versatility in forming various chiral compounds enables researchers to explore new drug candidates with improved pharmacological properties and reduced side effects.
Used in Material Science:
(R)-azetidin-2-ylmethanol hydrochloride may also have applications in the development of new materials and chemical technologies. Its unique structural features can be leveraged to create advanced materials with specific properties, such as improved stability, reactivity, or selectivity, which can be applied in various industrial processes.

Upstream product

• 228857-58-7 (R)-N-(tert-butoxycarbonyl)azetidine-2-carboxylic acid 
• 161511-90-6 (R)-1-t-butyloxycarbonyl-2-azetidinemethanol 

Relevant academic research and scientific papers

DISUBSTITUTED PYRAZOLE COMPOUNDS

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and no

Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode

A novel series of pyrrolidine-containing GPR40 agonists is described as a potential treatment for type 2 diabetes. The initial pyrrolidine hit was modified by moving the position of the carboxylic acid, a key pharmacophore for GPR40. Addition of a 4-cis-CF3 to the pyrrolidine improves the human GPR40 binding Ki and agonist efficacy. After further optimization, the discovery of a minor enantiomeric impurity with agonist activity led to the finding that enantiomers (R,R)-68 and (S,S)-68 have differential effects on the radioligand used for the binding assay, with (R,R)-68 potentiating the radioligand and (S,S)-68 displacing the radioligand. Compound (R,R)-68 activates both Gq-coupled intracellular Ca2+ flux and Gs-coupled cAMP accumulation. This signaling bias results in a dual mechanism of action for compound (R,R)-68, demonstrating glucose-dependent insulin and GLP-1 secretion in vitro. In vivo, compound (R,R)-68 significantly lowers plasma glucose levels in mice during an oral glucose challenge, encouraging further development of the series.

TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE

A compound represented by the general formula (1) [X1 and X2 represent hydrogen atom, a halogen atom, hydroxyl group and the like, R1 represents a phenyl group, R2 represents an alkyl group, an alkenyl group, or